BioPharma Dive September 26, 2025
Crinetics’ acromegaly treatment will go up against several entrenched medicines. Elsewhere, Bristol Myers moved to sell its psoriasis drug Sotyktu at a discount.
Today, a brief rundown of news involving Crinetics and the Food and Drug Administration, as well as updates from Eli Lilly, Biogen and Gossamer Bio that you may have missed.
Crinetics on Thursday won clearance from U.S. regulators to begin selling a new drug for the rare hormonal disorder acromegaly. Called Palsonify and, previously paltusotine, the drug is the first once-daily oral therapy for the condition and cleared for adults who aren’t eligible for corrective surgery or haven’t adequately responded to it. Palsonify is “poised to challenge the Goliaths of pharma,” among them Novartis and Pfizer, with...
Today's Sponsors
Today's Sponsor